ClinicalTrials.gg
CompletedNCT00603707WholeGutUpdated Aug 29, 2008

Assessment of Whole Gut Transit Time Using the SmartPill Capsule

An observational study in Constipation, sponsored by The SmartPill Corporation. Completed at 8 sites in United States. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2008-08-29.

Sponsored by The SmartPill Corporation · Observational

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
178
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Our null hypothesis states that the two techniques (Sitzmarks radioopaque markers and SmartPill) are equivalent and is demonstrated if the study population shows a correlation of 0.7 or higher.

Read the detailed description

The purpose of the study is to measure total gastrointestinal transit time using SmartPill GI Monitoring System with pH.p Capsule and compare the transit time determined by capsule transit to the conventional radioopaque marker technique.

Both techniques are simultaneously applied in normal and constipated adult populations.

02

Conditions studied

  • Constipation

Browse trials for

Keywords

  • capsule
  • constipation
  • whole gut transit
  • colonic transit
  • gastric emptying
  • small bowel transit
03

In context

Constipation

1,041 studies on the registry are indexed under Constipation; 139 are open to participants now.

This study's enrollment of 178 is above the median of 101 across 133 observational studies indexed under Constipation.

Browse Constipation studies →

Lead sponsor

The SmartPill Corporation is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

patients with constipation referred to a tertiary motility center

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females between ages of 18-80 years of age with functional constipation that fulfills the Rome II definition of functional constipation
  • Bowel movement frequency of \< 3 times per week but at least once per two weeks.
  • Constipation symptoms for at least 1 year duration.
  • Constipation, not abdominal pain, as the primary symptom.
  • Ability to stop fiber, laxatives, prokinetic agents, and narcotic analgesic agents 3 days prior to the study and during the 5 day study period.
  • Ability to stop proton pump inhibitors 7 days prior to the study and H2RAs for 3 days prior to the study.

Exclusion criteria

Exclusion Criteria:

  • Previous history of bezoars.
  • Prior GI surgery except for cholecystectomy, appendectomy, or Nissen fundoplication
  • Any abdominal surgery within the past 3 months
  • Known or history of inflammatory bowel disease
  • History of diverticulitis, diverticular stricture, and other intestinal strictures
  • Tobacco use within eight hours prior to capsule ingestion and during the initial 8 hour recording on Day 0 or the Ingestion visit.
  • Alcohol use within eight hours prior to capsule ingestion and throughout the entire monitoring period (5 days).
  • BMI > 38
  • Allergies to components of the SmartBar (Appendix IX).
  • Females of childbearing age who are not practicing birth control and/or are pregnant or lactating. (A urine pregnancy test will be performed on female subjects prior to capsule ingestion).
  • Cardiovascular, endocrine, renal, or other chronic disease likely to affect motility.
  • Use of medical devices such as pacemakers, infusion pumps, or insulin pumps.
  • Any contraindication to use of Fleets Enema or balloon expulsion test.
  • Uncontrolled diabetes with a hemoglobin A1C greater than 10.
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
178 participants (actual)

Groups and cohorts

  • Normal

    healthy adult subjects with no history or current gastrointestinal disorders or conditions

  • Constipated

    Adult subjects with functional constipation as define by Rome II criteria

06

What researchers measure

Primary outcomes

  1. whole gut transit time

    Time frame: 2 days and 5 days

Secondary outcomes

  1. Determine regional gut (gastric, small bowel, colonic) transit times

    Time frame: continuous time measure until caspule elimination

07

Study locations

8 sites
  • Mayo Clinic, Scottsdale
    Scottsdale, Arizona 85259, United States
  • University of Iowa
    Iowa City, Iowa 52242, United States
  • Kansas University Medical Center
    Kansas City, Kansas 66160, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • University of Michigan Medical Center
    Ann Arbor, Michigan 48109, United States
  • VA Medical Center
    Buffalo, New York 14215, United States
  • Wake Forest University Baptist Medical Center
    Winston-Salem, North Carolina 27157, United States
  • Temple University Medical Center
    Philadelphia, Pennsylvania 19140, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 29, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00603707
Lead sponsor
The SmartPill Corporation
First posted
Jan 29, 2008
Start date
Oct 2006
Primary completion
Jun 2008
Completion
Jun 2008
Last update
Aug 29, 2008

Study contacts

Henry Parkman, MD
study chair · Temple University Medical Center

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion